According to a new report from Intel Market Research, the global Buspirone Hydrochloride Tablets market was valued at USD 103 million in 2024 and is projected to reach USD 153 million by 2032, growing at a CAGR of 5.8% during the forecast period (2025–2032). This steady growth is driven by rising anxiety disorder prevalence and increasing adoption of non-benzodiazepine anxiolytics in clinical practice.

What are Buspirone Hydrochloride Tablets?

Buspirone Hydrochloride is a serotonin receptor agonist and dopamine receptor modulator prescribed for short-term management of anxiety disorders. Unlike traditional benzodiazepines, it demonstrates minimal sedation, addiction potential, or withdrawal symptoms, making it a preferred choice for generalized anxiety disorder (GAD) treatment. The drug is available in tablet form with standard dosages of 5mg, 10mg, and 15mg.

First approved by the FDA in 1986, buspirone has maintained its therapeutic relevance due to its unique mechanism of action and favorable safety profile. It is commercially available as generic medication worldwide, though some markets still carry branded versions under names like Buspar® (discontinued in the U.S. but available in select countries).

📥 Download FREE Sample Report:
Buspirone Hydrochloride Tablets Market - View in Detailed Research Report

Key Market Drivers

1. Increasing Global Anxiety Disorder Burden

The World Health Organization estimates that anxiety disorders affect 301 million people worldwide, with growing recognition of mental health conditions post-pandemic. Buspirone's advantages over benzodiazepines—particularly its lower risk of dependency—position it as a sustainable therapeutic option for chronic anxiety management. Recent clinical guidelines from the American Psychiatric Association have reinforced its role as first-line pharmacotherapy for mild-to-moderate GAD.

2. Expanding Geriatric Patient Pool

With 16% of the global population projected to be over 65 by 2050 (United Nations data), geriatric-friendly anxiolytics are witnessing heightened demand. Buspirone's favorable pharmacokinetics in elderly patients—including reduced cognitive impairment risks compared to alternatives—make it particularly suitable for this demographic. Cardiology associations increasingly recommend it for anxiety management in patients with cardiovascular comorbidities.

Market Challenges

While the outlook remains positive, several factors constrain market expansion:

• Delayed onset of action: Requires 2-4 weeks for full therapeutic effect, limiting adoption in acute settings

• Drug interaction concerns: Contraindicated with MAO inhibitors and impacted by CYP3A4 inducers/inhibitors

• Patent expiry: Universal generic availability suppresses brand premium pricing opportunities

Dosage-Specific Growth Trends

The market demonstrates distinct dynamics across dosage forms:

• 5mg tablets: Preferred for dose titration and elderly patients

• 10mg tablets: Most commonly prescribed maintenance dose

• 15mg tablets: Gaining traction for severe cases requiring BID/TID dosing

Regional Market Insights

• North America: Accounts for dominant market share due to high mental health awareness and established generic drug infrastructure

• Europe: Shows steady growth with increasing emphasis on non-addictive anxiolytics in clinical guidelines

• Asia-Pacific: Emerging as high-growth region with improving mental healthcare access and local generic production

Market Segmentation

By Type

• 5mg
• 10mg
• 15mg

By Application

• Hospital
• Clinic
• Others

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa

📘 Get Full Report Here:
Buspirone Hydrochloride Tablets Market - View in Detailed Research Report

Competitive Landscape

The market features several established generic manufacturers, with key players including:

• Teva Pharmaceuticals
• PKU HealthCare
• Jiangsu Nhwa Pharmaceutical
• Beijing Huasu Pharmaceuticals

Report Coverage

• Market size projections through 2032
• Dosage-form specific adoption trends
• Regulatory landscape analysis
• Pricing and reimbursement scenarios
• Competitive benchmarking

📥 Download FREE Sample Report:
Buspirone Hydrochloride Tablets Market - View in Detailed Research Report

About Intel Market Research

Intel Market Research is a leading provider of strategic intelligence, offering actionable insights in biotechnology, pharmaceuticals, and healthcare infrastructure. Our research capabilities include:

• Real-time competitive benchmarking
• Global clinical trial pipeline monitoring
• Country-specific regulatory and pricing analysis
• Over 500+ healthcare reports annually

Trusted by Fortune 500 companies, our insights empower decision-makers to drive innovation with confidence.

🌐 Website: https://www.intelmarketresearch.com
📞 International: +1 (332) 2424 294
📞 Asia-Pacific: +91 9169164321
🔗 LinkedIn: Follow Us